TLSA - Tiziana Life Sciences Ltd

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing foralumab, an anti-CD3 antibody delivered via nasal spray, to stimulate regulatory T-cell (Treg) production and reduce the inflammatory processes that drive neurodegeneration.

Sep 03, 2026 11:27 AM • proactiveinvestors.com

Dow climbs as stocks rebound on earnings, falling Treasury yields

3:40pm: Small cap wrap Tiziana Life Sciences Ltd (NASDAQ:TLSA) received a Buy rating and $7 price target from BTIG, which highlighted its nasal anti-CD3...

Sep 03, 2026 07:44 AM • proactiveinvestors.com

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” is scheduled for 4:30 pm to 6:30 pm Eastern Time during the Scientific Poster Session.

Aug 24, 2026 04:49 AM • proactiveinvestors.com

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” will be presented by Dr. Pinar Uysal today, Monday, August 24, 2026, from 4:30–6:30 p.m. ET during the Scientific Poster Session in the Nexus Pavilion at the Hyatt Regency Grand Cypress Resort in Orlando, Florida.

Aug 24, 2026 03:00 AM • globenewswire.com

Gemini Pro delay leaves Google with an empty flagship tier

Polymarket, the crypto-based prediction platform, puts the probability of no new Gemini Pro release before 30 September at 69%. Every specific launch date...

Aug 24, 2026 02:42 AM • proactiveinvestors.com

Tiziana Life Sciences announces CEO share purchase

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO Ivor Elrifi increased his stake in the company through the purchase of 321,423 common shares on Nasdaq...

Aug 06, 2026 01:40 AM • proactiveinvestors.com

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 667,000 of the Company's common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,472,261 common shares.

Aug 04, 2026 03:00 AM • globenewswire.com

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ:TLSA) on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial.

Jul 31, 2026 09:32 AM • benzinga.com

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal foralumab, with PET scans showing reductions in brain inflammation following treatment. The company said quantitative analysis of PET imaging demonstrated reductions in inflammatory activity in brain regions commonly affected by MSA, including the basal ganglia and cerebellar white matter.

Jul 31, 2026 04:56 AM • proactiveinvestors.com

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.

Jul 31, 2026 03:00 AM • globenewswire.com

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its...

Jul 31, 2026 12:55 AM • proactiveinvestors.com

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr.

Jul 22, 2026 03:00 AM • globenewswire.com

Qualcomm raises long-term targets as analysts highlight data center, edge AI opportunities

Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its investor day, prompting analysts at Bank of America and...

Jun 25, 2026 07:31 AM • proactiveinvestors.com

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS), with topline data expected in late Q3 or early Q4 2026. The company said results are planned to be presented at the 10th joint ACTRIMS-ECTRIMS meeting in Toronto in October 2026.

Jun 25, 2026 05:06 AM • proactiveinvestors.com

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the last patient in its ongoing Phase 2a clinical trial has received their first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

Jun 25, 2026 03:00 AM • globenewswire.com

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr.

Jun 15, 2026 03:00 AM • globenewswire.com

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City.

May 28, 2026 03:00 AM • globenewswire.com

Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. CEO Ivor Elrifi and...

May 28, 2026 02:07 AM • proactiveinvestors.com

FedEx sum-of-the-parts valuation points to upside as freight spin-off approaches, UBS says

UBS is sticking with a Buy rating on FedEx Corp (NYSE:FDX, XETRA:FDX) and a price target of $445, as the company gets ready to spin off its freight business...

May 25, 2026 02:32 AM • proactiveinvestors.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded access study data suggesting the investigational therapy may deliver clinically meaningful benefits for patients. Speaking with Proactive, CEO Ivor Elrifi said the placebo-controlled study has fully enrolled 48 participants across several leading US institutions, including Harvard, Yale, Cornell, Johns Hopkins, UMass Buffalo and Thomas Jefferson.

May 22, 2026 01:06 PM • proactiveinvestors.com